OCGN Stock Price, Ocugen Inc Quote, Chart

Market Summary

USD1.24-0.08

Delayedas of 22 Apr 2024, 12:10 pm

-6.06%

OCGN Stock Price

View Fullscreen

OCGN RSI Chart

OCGN Valuation

Market Cap

339.7M

Price/Earnings (Trailing)

-5.38

EV/EBITDA

-4.8

Price/Free Cashflow

-4.68

MarketCap/EBT

-5.38

OCGN Price/Sales (Trailing)

OCGN Profitability

Return on Equity

-155.5%

Return on Assets

-97.72%

Free Cashflow Yield

-21.35%

OCGN Fundamentals

OCGN Earnings

Earnings (TTM)

-63.1M

Earnings Growth (Yr)

56.73%

Earnings Growth (Qtr)

32.97%

Breaking Down OCGN Revenue

52 Week Range

0.391.32

(Low)(High)

Last 7 days

-22.8%

Last 30 days

6.5%

Last 90 days

158.8%

Trailing 12 Months

60.7%

How does OCGN drawdown profile look like?

OCGN Financial Health

Current Ratio

2.51

Debt/Equity

0.07

Debt/Cashflow

-22.16

OCGN Investor Care

Shares Dilution (1Y)

13.65%

Diluted EPS (TTM)

-0.27

Tracking the Latest Insider Buys and Sells of Ocugen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 03, 2024	musunuri shankar	sold (taxes)	-117,673	0.653	-180,204	chief executive officer
Jan 03, 2024	upadhyay arun	sold (taxes)	-27,186	0.653	-41,633	see remarks
Sep 16, 2023	upadhyay arun	sold (taxes)	-345	0.41	-842	see remarks
Jun 16, 2023	upadhyay arun	sold (taxes)	-467	0.51	-917	chief scientific officer
Jun 14, 2023	zhang junge	bought	99,998	0.4993	200,278	-
Feb 16, 2023	musunuri shankar	sold	-108,000	1.08	-100,000	chief executive officer
Feb 16, 2023	musunuri shankar	acquired	33,000	0.33	100,000	chief executive officer
Jan 17, 2023	musunuri shankar	acquired	51,000	0.51	100,000	chief executive officer
Jan 17, 2023	musunuri shankar	sold	-128,000	1.28	-100,000	chief executive officer
Jan 03, 2023	musunuri shankar	sold (taxes)	-47,346	1.25	-37,877	chief executive officer

Which funds bought or sold OCGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	Cedar Mountain Advisors, LLC	unchanged	-	106	164	-%
Apr 11, 2024	David J Yvars Group	new	-	34,719	34,719	0.02%
Apr 11, 2024	Capital CS Group, LLC	unchanged	-	10,650	16,400	0.02%
Apr 10, 2024	Wedmont Private Capital	unchanged	-	15,651	25,248	-%
Apr 05, 2024	CWM, LLC	unchanged	-	8,000	12,000	-%
Apr 03, 2024	Versant Capital Management, Inc	sold off	-100	-58.00	-	-%
Apr 01, 2024	Global Wealth Strategies & Associates	unchanged	-	319	492	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-400	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.96	2,152,730	6,922,950	-%
Mar 04, 2024	VIMA LLC	new	-	210	210	-%

Are Funds Buying or Selling OCGN?

Are funds buying OCGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OCGN

No. of Funds

Unveiling Ocugen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	4.69%	12,039,918	SC 13G/A
Jan 22, 2024	state street corp	0.33%	835,826	SC 13G/A
Jul 07, 2023	blackrock inc.	1.5%	3,907,414	SC 13G/A
Feb 10, 2023	state street corp	13.76%	30,121,024	SC 13G/A
Feb 09, 2023	vanguard group inc	5.42%	11,859,143	SC 13G/A
Feb 01, 2023	blackrock inc.	6.9%	15,061,361	SC 13G/A
Apr 11, 2022	state street corp	13.57%	29,153,704	SC 13G/A
Feb 11, 2022	state street corp	7.04%	14,017,619	SC 13G
Feb 04, 2022	blackrock inc.	6.5%	12,931,131	SC 13G
Feb 10, 2021	vanguard group inc	5.60%	9,074,993	SC 13G

Recent SEC filings of Ocugen Inc

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	S-8	Employee Benefits Plan
Apr 18, 2024	S-3	S-3
Apr 17, 2024	4	Insider Trading
Apr 16, 2024	10-K	Annual Report
Apr 08, 2024	8-K	Current Report
Apr 02, 2024	8-K	Current Report
Apr 01, 2024	NT 10-K	NT 10-K
Apr 01, 2024	8-K	Current Report
Mar 21, 2024	8-K	Current Report
Mar 20, 2024	8-K	Current Report

Peers (Alternatives to Ocugen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Ocugen Inc News

Latest updates

Ocugen Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-13.6%	65.00	75.00	89.00	96.00	109	116	130	142	106	116	124	54.00	27.00	21.00	24.00	12.00	17.00	24.00	4.00	15.00	2.00
Current Assets	-24.0%	43.00	57.00	73.00	84.00	98.00	107	123	138	103	113	122	51.00	26.00	20.00	23.00	11.00	16.00	23.00	3.00	8.00	2.00
Cash Equivalents	-26.2%	39.00	53.00	71.00	68.00	78.00	102	115	130	95.00	107	116	45.00	24.00	19.00	15.00	3.00	8.00	15.00	1.00	0.00	2.00
Net PPE	19.5%	17.00	14.00	12.00	8.00	6.00	5.00	3.00	2.00	1.00	-	-	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	47.2%	24.00	16.00	19.00	20.00	25.00	21.00	16.00	11.00	10.00	9.00	8.00	7.00	6.00	6.00	9.00	5.00	6.00	37.00	10.00	20.00	15.00
Current Liabilities	53.5%	17.00	11.00	13.00	16.00	18.00	15.00	10.00	8.00	7.00	6.00	5.00	4.00	4.00	4.00	7.00	3.00	5.00	35.00	9.00	2.00	14.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	1.00	4.00	-	-	-	2.00	1.00	7.00
Long Term Debt	87.3%	3.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	-	1.00
LT Debt, Current	-100.0%	-	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	-	1.00
Shareholder's Equity	-30.5%	41.00	58.00	70.00	76.00	84.00	95.00	114	131	96.00	107	116	46.00	22.00	14.00	15.00	7.00	11.00	-	-	-	-
Retained Earnings	-7.3%	-286	-266	-252	-229	-213	-191	-169	-149	-131	-117	-106	-80.38	-73.30	-69.51	-59.04	-55.40	-51.48	-63.86	-41.09	-226	31.00
Additional Paid-In Capital	0.5%	324	322	320	303	295	284	281	279	226	222	221	125	93.00	82.00	72.00	62.00	62.00	51.00	35.00	220	18.00
Shares Outstanding	0.0%	257	256	256	226	222	213	216	206	199	199	191	186	-	-	-	-	-	-	-	-	-
Float	-	-	-	137	-	-	-	483	-	-	-	1,600	-	-	-	29.00	-	-	-	18.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	17.5%	-11,302	-13,706	-18,806	-18,240	-16,914	-14,302	-13,797	-15,066	-12,804	-8,053	-21,801	-5,283	-4,283	-2,653	-3,087	-4,686	-8,743	-2,118	-3,363	-2,667	-2,786
Share Based Compensation	-100.0%	-	2,174	2,632	2,689	2,668	2,495	2,079	3,299	2,683	1,347	2,095	833	163	126	149	222	164	193	112	415	329
Cashflow From Investing	19.1%	-2,722	-3,365	5,723	3,441	-15,295	-83.00	-1,366	-223	-192	-350	-1,013	-261	-251	-22.00	19.00	-53.00	-20.87	-2,204	-121	-10.58	-
Cashflow From Financing	145.7%	16.00	-35.00	15,404	5,496	8,175	962	236	50,102	605	110	93,664	26,297	9,467	6,813	14,843	488	907	18,945	3,855	1,359	1,931

OCGN Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Total revenue	$ 3,699	$ 485	$ 443	$ 466	$ 643	$ 500	$ 928	$ 1,143	$ 4,627	$ 1,609	$ 6,036	$ 2,488
Operating expenses
Research and development	7,048	14,574	10,172	17,937	11,602	9,393	24,746	20,995	31,794	38,932	39,573	56,159
General and administrative	9,082	9,451	8,306	7,639	10,617	10,137	17,757	20,754	26,839	28,393	31,994	35,400
Total operating expenses	16,130	24,025	18,478	25,576	22,219	19,530	42,503	41,749	58,633	67,325	71,567	91,559
Loss from operations	(12,431)	(23,540)	(18,035)	(25,110)	(21,576)	(19,030)	(41,575)	(40,606)	(54,006)	(65,716)	(65,531)	(89,071)
Other income (expense), net	714	475	709	1,197	94	15	1,184	109	1,898	1,306	2,453	2,267
Net loss	(11,717)	(23,065)	(17,326)	(23,913)	(21,482)	(19,015)	(40,391)	(40,497)	(52,108)	(64,410)	(63,078)	(86,804)
Other comprehensive income (loss)
Foreign currency translation adjustment	5	(2)	(1)	20	10	0	(3)	10	2	30	(5)	25
Unrealized gain (loss) on marketable securities	0	(1)		0	0		(1)	0	(1)	0	(1)	1
Comprehensive loss	$ (11,712)	$ (23,068)	$ (17,327)	$ (23,893)	$ (21,472)	$ (19,015)	$ (40,395)	$ (40,487)	$ (52,107)	$ (64,380)	$ (63,084)	$ (86,778)
Shares used in calculating net loss per common share - basic (in shares)	256,492,558	238,311,498	225,523,627	216,591,011	215,862,977	205,693,498	231,952,888	210,806,330	240,222,667	212,755,746	244,327,057	214,600,051
Shares used in calculating net loss per common share - diluted (in shares)	256,492,558	238,311,498	225,523,627	216,591,011	215,862,977	205,693,498	231,952,888	210,806,330	240,222,667	212,755,746	244,327,057	214,600,051
Net loss per share of common stock - basic (in USD per share)	$ (0.05)	$ (0.10)	$ (0.08)	$ (0.11)	$ (0.10)	$ (0.09)	$ (0.17)	$ (0.19)	$ (0.22)	$ (0.30)	$ (0.26)	$ (0.40)
Net loss per share of common stock - diluted (in USD per share)	$ (0.05)	$ (0.10)	$ (0.08)	$ (0.11)	$ (0.10)	$ (0.09)	$ (0.17)	$ (0.19)	$ (0.22)	$ (0.30)	$ (0.26)	$ (0.40)
Collaborative arrangement revenue
Total revenue	$ 3,699	$ 485	$ 443	$ 466	$ 643	$ 500	$ 928	$ 1,143	$ 4,627	$ 1,609	$ 6,036	$ 2,488
Operating expenses
Research and development											$ 5,300	$ 9,100

OCGN Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 39,462	$ 53,477	$ 70,578	$ 68,259	$ 77,563	$ 101,602	$ 115,005	$ 129,771
Marketable securities	0	0	0	8,462	13,371	0	0	0
Prepaid expenses and other current assets	3,509	3,081	2,874	7,680	7,558	5,895	7,564	8,256
Total current assets	42,971	56,558	73,452	84,401	98,492	107,497	122,569	138,027
Property and equipment, net	17,290	14,469	11,720	7,952	6,053	4,517	3,153	1,921
Other assets	4,286	3,660	3,804	3,946	4,087	4,225	4,366	1,628
Total assets	64,547	74,687	88,976	96,299	108,632	116,239	130,088	141,727
Current liabilities
Accounts payable	3,172	2,921	3,881	8,092	8,062	6,460	5,921	3,896
Accrued expenses and other current liabilities	13,343	14,993	18,826	16,722	19,971	17,620	11,728	9,151
Operating lease obligations	574	540	526	512	498	443	314	254
Total current liabilities	17,089	19,730	24,499	26,582	28,531	24,523	17,963	13,301
Non-current liabilities
Operating lease obligations, less current portion	3,567	3,164	3,308	3,449	3,587	3,764	3,892	1,180
Long term debt, net	2,800	1,495	1,472	1,058	2,289	2,265	1,750	1,731
Other non-current liabilities	527	497	455	309	244	0	0	0
Total non-current liabilities	6,894	5,156	5,235	4,816	6,120	6,029	5,642	2,911
Total liabilities	23,983	24,886	29,734	31,398	34,651	30,552	23,605	16,212
Commitments and contingencies (Note 15)
Stockholders' equity
Common stock; $0.01 par value; 295,000,000 shares authorized; 256,688,304 and 221,721,182 shares issued, and 256,566,804 and 221,599,682 shares outstanding at December 31, 2023 and 2022, respectively	2,567	2,566	2,566	2,265	2,217	2,168	2,163	2,158
Treasury stock, at cost, 121,500 shares at December 31, 2023 and 2022	(48)	(48)	(48)	(48)	(48)	(48)	(48)	(48)
Additional paid-in capital	324,191	322,452	320,181	303,073	294,874	284,231	281,139	278,704
Accumulated other comprehensive income	20	27	22	25	26	30	10	0
Accumulated deficit	(286,167)	(275,197)	(263,480)	(240,415)	(223,089)	(200,695)	(176,782)	(155,300)
Total stockholders' equity	40,564	49,801	59,242	64,901	73,981	85,687	106,483	125,515	$ 91,200
Total liabilities and stockholders' equity	64,547	74,687	88,976	96,299	108,632	116,239	130,088	141,727
Series A Convertible Preferred Stock
Stockholders' equity
Preferred stock issued	0	0	0	0	0	0	0	0
Series B Convertible Preferred Stock
Stockholders' equity
Preferred stock issued	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1	$ 5,000

About Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

CEO	Dr. Shankar Musunuri M.B.A., MBA, Ph.D.
WEBSITE	ocugen.com
INDUSTRY	Biotechnology
EMPLOYEES	84

Ocugen Inc Frequently Asked Questions

What is the ticker symbol for Ocugen Inc? What does OCGN stand for in stocks?

OCGN is the stock ticker symbol of Ocugen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ocugen Inc (OCGN)?

As of Fri Apr 19 2024, market cap of Ocugen Inc is 339.67 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCGN stock?

You can check OCGN's fair value in chart for subscribers.

What is the fair value of OCGN stock?

You can check OCGN's fair value in chart for subscribers. The fair value of Ocugen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ocugen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OCGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ocugen Inc a good stock to buy?

The fair value guage provides a quick view whether OCGN is over valued or under valued. Whether Ocugen Inc is cheap or expensive depends on the assumptions which impact Ocugen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCGN.